Nemifitide
Overview
Nemifitide is a synthetic pentapeptide analog of the endogenous neuropeptide alpha-melanocyte-stimulating hormone (alpha-MSH). It acts on melanocortin receptors, particularly MC4, to modulate inflammatory pathways, oxidative stress, and neuronal excitability. The peptide has been investigated for neuroprotection in settings of acute brain injury and neurodegenerative disease.
Key Research Findings
A phase II trial in hemorrhagic stroke patients did not demonstrate significant improvement in functional outcomes or mortality. Additional small studies in traumatic brain injury have been conducted, but robust clinical efficacy data remain limited and no regulatory approvals have been obtained.
Intravenous
Investigational
Interested in Nemifitide?
Find a verified provider experienced with Nemifitide protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Nemifitide ProviderRelated Peptides
Semax
FDA ApprovedA synthetic heptapeptide analog of the ACTH(4-7) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) with nootropic and neuroprotective properties. Semax modulates BDNF and NGF expression, enhances monoaminergic neurotransmission, and provides neuroprotection through anti-oxidant and anti-inflammatory mechanisms. It crosses the blood-brain barrier via intranasal administration.
Selank
InvestigationalA synthetic analog of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with an added Pro-Gly-Pro sequence for stability. Selank exhibits anxiolytic activity comparable to benzodiazepines without sedation, dependence, or withdrawal effects. It modulates the expression of BDNF, serotonin, dopamine, and norepinephrine, and influences IL-6 and GABA receptor expression.
Cerebrolysin
InvestigationalA porcine brain-derived peptide preparation consisting of low-molecular-weight neuropeptides and free amino acids that mimic the action of endogenous neurotrophic factors. Cerebrolysin exhibits neurotrophic activity similar to BDNF, GDNF, and CNTF, promoting neuronal survival, synaptic plasticity, and neurogenesis. It modulates GSK-3beta, CDK5, and calcineurin-NFAT signaling cascades involved in neurodegeneration.
P21 (Peptide)
Research PhaseA small synthetic peptide derived from the active region of ciliary neurotrophic factor (CNTF) designed to promote neurogenesis and synaptic plasticity. P21 is a tetrapeptide that crosses the blood-brain barrier and enhances dentate gyrus neurogenesis by increasing BDNF expression. Unlike full-length CNTF, P21 does not activate the JAK-STAT pathway or produce the anorectic and immunogenic effects of the parent protein.